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The effect of PTC124 on 
choroideremia fibroblasts and iPSC-
derived RPE raises considerations 
for therapy
Simona Torriano1,2, Nejla Erkilic1,2, David Baux  3, Nicolas Cereso1,2, Valerie De Luca1,2, 
Isabelle Meunier  1,4,5, Mariya Moosajee6, Anne-Francoise Roux3,7, Christian P. Hamel1,2,4,5 & 
Vasiliki Kalatzis  1,2
Inherited retinal dystrophies (IRDs) are caused by mutations in over 200 genes, resulting in a range of 
therapeutic options. Translational read-through inducing drugs (TRIDs) offer the possibility of treating 
multiple IRDs regardless of the causative gene. TRIDs promote ribosomal misreading of premature stop 
codons, which results in the incorporation of a near-cognate amino acid to produce a full-length protein. 
The IRD choroideremia (CHM) is a pertinent candidate for TRID therapy, as nonsense variants cause 30% 
of cases. Recently, treatment of the UAA nonsense-carrying CHM zebrafish model with the TRID PTC124 
corrected the underlying biochemical defect and improved retinal phenotype. To be clinically relevant, 
we studied PTC124 efficiency in UAA nonsense-carrying human fibroblasts and induced pluripotent 
stem cell-derived retinal pigment epithelium, as well as in a UAA-mutated CHM overexpression system. 
We showed that PTC124 treatment induces a non-significant trend for functional rescue, which could 
not be improved by nonsense-mediated decay inhibition. Furthermore, it does not produce a detectable 
CHM-encoded protein even when coupled with a proteasome inhibitor. We suggest that drug efficiency 
may depend upon on the target amino acid and its evolutionary conservation, and argue that patient 
cells should be screened in vitro prior to inclusion in a clinical trial.
The retina lines the back of the eye and is responsible for capturing, converting and transmitting the light signal 
to the brain for image interpretation. It is made up of the neuroretina, which contains the light-sensing photore-
ceptors, and the supporting retinal pigment epithelium (RPE). Inherited retinal dystrophies (IRDs) are a group 
of clinically heterogeneous disorders that are characterised by degeneration of the photoreceptors and/or RPE. 
IRDs are also genetically heterogeneous with over 200 causative genes identified to date (https://sph.uth.tmc.edu/
Retnet). Collectively, they have a prevalence of ~1 in 2500 individuals1. As IRDs are mainly monogenic, they have 
received much focus as therapeutic targets for gene-dependent approaches, such as viral vector-mediated gene 
replacement2–5.
However, it is unlikely that a successful gene replacement approach will be developed for all IRD genes in 
the near future. It is thus important to study in parallel other therapeutic options. Mutation-dependent thera-
pies are particularly interesting, as they would reach a larger target population. One option is pharmacological 
compounds, which, if already approved for human use, could result in rapid clinical translation in the event of 
positive results. An example is translational read-through inducing drugs (TRIDs). TRIDs work on nonsense 
mutations by promoting ribosomal misreading of the premature stop codon and resulting in the incorporation of 
a near-cognate amino acid. This produces a full-length protein, which in some cases can be functional6. The most 
common examples are the widely used class of antibiotics, the aminoglycosides. Although approved for human 
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use, they have the disadvantage of significant oto-7 and nephrotoxicity8 that precludes long-term use9. In addition, 
retinal toxicity has also been reported following intraocular administration10,11.
Studies have been aimed at developing and testing alternative TRIDs with lower side effects12–14. One such 
TRID is PTC12415, which has been widely tested and reported to have the efficiency of aminoglycosides with-
out the associated toxicity. Furthermore, this molecule reached phase 3 clinical trial testing for cystic fibrosis 
(NCT02139306) and Duchenne muscular dystrophy (NCT01826487). In terms of ocular disease, PTC124 has 
been investigated as a potential TRID for Usher syndrome 1C16, retinitis pigmentosa17,18 and aniridia19. In addi-
tion, the treatment of aniridia by PTC124 will be further investigated in a clinical trial (NCT02647359).
The potential interest of TRID therapy increases proportionally with the prevalence of nonsense mutations 
for a given disease. Along this line, the IRD choroideremia (CHM) is a particularly pertinent candidate as 30% of 
causative mutations are nonsense variants20. Therefore, if successful, this approach would allow the treatment of 
a non-negligible number of patients. CHM is characterised by a progressive degeneration of the photoreceptors, 
RPE and underlying choroid. At the clinical level, patients present with night blindness in childhood, and evolve 
to legal blindness from 40 years of age21. CHM is an X-linked disorder due to mutations in the gene CHM that 
encodes Rab escort protein 1 (REP1)22. REP1 acts as a chaperon for Rab guanosine triphosphatases, transporting 
them to the enzyme Rab geranylgeranyl transferase (RGGTase) for prenylation. REP1 then delivers the prenylated 
Rabs to their target membranes, where they act as regulators of vesicular trafficking23. Thus, in the absence of 
REP1, unprenylated Rabs accumulate in the cytosol.
Interestingly, a zebrafish model of CHM due to a nonsense UAA mutation has been described24,25. This model 
arises from a c.96C > T transition in exon 2 of the chm gene that gives rise to the p.Gln33* alteration, which 
results in lethality from day 5 post-fertilisation (dpf). Nonetheless, the mutant larvae have been exploited as a 
model for TRID therapy of CHM. It was shown that aminoglycosides (gentamicin and paromomycin) could 
significantly preserve retinal structure and increase survival of the chm−/y zebrafish larvae26. We more recently 
showed that PTC124 treatment of chm−/y larvae, in comparison to gentamicin, corrected the prenylation defect, 
improved the retinal phenotype and increased survival27.
As a clinically pertinent complement to that study, we have tested PTC124 efficiency in human cells car-
rying a UAA nonsense mutation. We tested the ability of PTC124 to improve the prenylation defect in patient 
fibroblasts and in RPE derived from patient induced pluripotent stem cells (iPSC). A trend for functional rescue 
was observed, albeit not significant. In silico analysis and 3D modelling suggest that, if read-through is taking 
place, drug efficiency may depend on the conservation and type of the target amino acid, and its localisation 
with regards to REP1 structure and Rab binding. However, PTC124 treatment did not result in the expression 
of detectable REP1 in the patient cells or in an overexpression system comprising CHM:EGFP fusion constructs 
carrying the UAA mutation. We highlight considerations that should be taken into account when considering 
TRID therapy for this and other disorders, and suggest that patient cells should be used for drug screening prior 
to inclusion in a clinical trial.
Results
Effect of the c.772A > T variant on CHM expression. We performed and cultured a skin biopsy of the 
patient CHM3, previously identified as carrying the variant c.772A > T in the CHM gene. This variant introduces 
a premature UAA stop codon at the position of a lysine residue, p.Lys258*, in REP1. We confirmed the presence 
of the c.772A > T variant in the emerging CHM3 fibroblasts by sequencing. In wild-type cells, c.772 corresponds 
to the first position of an AAA codon (Fig. 1A). In CHM3 cells, a T is found at the same position, which gives 
rise to a TAA codon in the DNA sequence (Fig. 1B). qPCR amplification using CHM-specific primers in exon 
5 showed that the mRNA levels of CHM3 were significantly reduced to 20% of wild-type (p < 0.05; Fig. 1C), 
suggesting nonsense-mediated decay (NMD). The CHM3 mRNA levels were not significantly different to those 
of another patient, CHM1, who carries a deletion of exon 8, which results in a frame shift and a premature stop 
codon28. Lastly, the mutant p.Lys258* REP1 was not detected in CHM3 cells by western blot analysis (Fig. 1D), 
which was consistent with previous results for CHM128,29.
Thus, the persistence of a CHM transcript in CHM3 was compatible with a translational read-through 
approach. Furthermore, the absence of REP1 expression represented a putative criterion to evaluate read-through.
Effect of PTC124 treatment on CHM3 fibroblasts. Initially, we tested for an effect of PTC124 treatment 
on CHM mRNA levels by qPCR analysis of fibroblasts. All working concentrations of PTC124 were kept at 0.2% 
DMSO, therefore, as a negative control, CHM3 cells were treated with 0.2% DMSO. Wild-type CHM mRNA lev-
els remained significantly higher than DMSO-treated cells (p < 0.05; Fig. 2A). PTC124 treatment of CHM3 cells, 
regardless of the dose, did not significantly alter mRNA levels beyond that of DMSO alone (Fig. 2A). Consistently, 
REP1 was not detected by western blot analysis following treatment in the patient cell lysates (data not shown). 
To determine the limit of detection by western blot analysis, we performed serial dilutions of wild-type cell lysates 
and assayed for REP1. A progressively fainter REP1 band was observed down to a 1:10 dilution; a REP1 band 
could not be detected from 1:50 (Supplementary Fig. S1). This placed the limit of REP1 detection to between 2 
and 10% of wild-type levels.
We tested if PTC124 treatment could improve the biochemical defect despite the absence of detectable REP1. 
We previously showed that the elevated levels of unprenylated cytosolic Rabs in CHM patients can be used as a 
read-out for therapy screening28,29. Unprenylated Rab levels can be detected using an in vitro prenylation assay, 
which relies on the addition of recombinant RGGTase, REP1, and biotinylated prenyl donor to the cytosolic 
cell fraction. If this fraction contains a Rab pool available for in vitro prenylation, the integrated biotin will be 
detected by western blot analysis using HRP-conjugated streptavidin. The quantity of biotinylated Rabs will thus 
be inversely proportional to endogenous REP1 activity30. We tested for a PTC124 effect on function by assaying 
for a reduction in the cytosolic Rab pool. One representative assay is shown in Fig. 2B, where wild-type fibroblasts 
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show low levels of biotinylated Rabs in comparison to CHM3 fibroblasts. Quantification of multiple assays 
showed that the biotinylated Rab levels of non- or DMSO-treated CHM3 fibroblasts were significantly higher 
than wild-type (p < 0.05; Fig. 2C). A non-significant dose-dependent effect was observed following PTC124 treat-
ment: Doses inferior to 0.1 µg/ml tended to decrease Rab levels and the most pronounced reduction was 30%; 
doses superior to 0.5 µg/ml tended to increase Rab levels.
Taken together, PTC124 treatment did not alter CHM mRNA levels or result in detectable REP1 expression. 
Depending on the dose, a non-significant decrease in cytosolic Rab levels was observed.
Effect of NMD suppression on PTC124 treatment. To determine whether PTC124 was more effective 
if mRNA levels were increased, we treated CHM3 fibroblasts with an NMD inhibitor, cycloheximide (CHX). 
qPCR analysis showed that CHX treatment increased CHM transcript levels, as compared to non-treated con-
trols, proportionally to the incubation time (Fig. 3A). NMD was significantly inhibited (p < 0.05) after 24 h treat-
ment. Combined CHX and PTC124 treatment of CHM3 cells abolished the biotinylated Rab population (Fig. 3B). 
However, the same effect was seen in cells treated with CHX alone. To exclude a side effect due to prolonged CHX 
treatment, we analysed shorter time courses on CHM3 and wild-type cells. A progressive reduction in biotiny-
lated Rab levels in CHX-treated CHM3 cells was seen over time: 80% decrease at 2 h; 95% at 4 h, and 99% at 8 h 
(Fig. 3C). CHX-treated wild-type cells showed a similar time-dependent decrease: 60% at 2 h; 80% at 4 h, and 
90% at 8 h. We also assayed the effect of lower CHX concentrations and a shorter time point in the presence and 
absence of PTC124, and observed a reduction in Rab levels for all conditions (Supplementary Fig. S2). Moreover, 
a decrease in Rab27a levels was detectable by western blot analysis, from 2 h in CHM3 cells and from 8 h in 
wild-type cells after CHX treatment (Fig. 3D). In contrast, REP1 and β-actin levels were unchanged.
In conclusion, NMD suppression by CHX could not be used to enhance read-through due to a nonsense 
mutation-independent effect of this compound on Rab expression.
Generation of CHM3 iPSC-derived RPE. Although CHM is expressed ubiquitously, it is mainly the retina 
that shows a clinical phenotype. To determine whether a significant functional improvement with PTC124 could 
be obtained in a more clinically relevant cell type, we reprogrammed patient fibroblasts into iPSC for retinal dif-
ferentiation. The iPSC were validated as pluripotent by qPCR analysis for the onset of expression of the host pluri-
potency genes OCT3/4, LIN28, SOX2 and NANOG (Fig. 4A–D), and as genetically stable by karyotype analysis 
Figure 1. Effect of the c.772A>T variant in patient fibroblasts. (A) Sequence analysis of the genomic DNA 
of the wild-type CHM sequence from position c.762–782 shows the presence of an adenine at position c.772. 
(B) Sequence analysis of the same region in the genomic DNA of patient CHM3 shows the A>T transition 
at position c.772 resulting in a TAA codon. (C) qPCR analysis of CHM expression (in relative units) shows 
that the c.772A>T variant in CHM3 fibroblasts results in mRNA levels that are significantly reduced by 
5-fold compared to wild-type (WT) cells and comparable to those of CHM1 fibroblasts. Data are expressed as 
mean ± SEM, n = 3; Mann and Whitney test *p < 0.05. (D) Western blot analysis shows the presence of REP1 in 
wild-type fibroblasts following hybridisation with a specific anti-REP1 antibody as compared to the absence of 
a detectable protein in CHM3 cells. Hybridisation with an antibody against β-actin serves as a loading control. 
Bands were cropped from the same gel with different exposure times for REP1 and β-actin.
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(Fig. 4E). iPSC were then differentiated into RPE, one of the primary tissues affected in CHM. We have previously 
shown that iPSC-derived RPE from CHM patients is morphologically and functionally characteristic of the RPE 
in vivo28,29. The CHM3 iPSC-derived pigmented monolayer (Fig. 4F) was assayed by qPCR analysis to verify the 
expression of RPE markers, which were upregulated as compared to fibroblasts (Fig. 4G). We also measured the 
transepithelial resistance (TER) to verify that the iPSC-derived RPE formed tight junctions. Consistent with 
ZO1 expression, the monolayer was confirmed as tight from 5 weeks post-differentiation when the TER values 
exceeded 150 Ω/cm2 (Fig. 4H). The TER values remained stable from 7 weeks post-differentiation.
Thus, we generated bona fide RPE for patient CHM3 to assay translational read-through in a more clinically 
pertinent cell type.
Effect of PTC124 treatment on CHM3 iPSC-derived RPE. We first assayed CHM mRNA levels in the 
iPSC-derived RPE by qPCR analysis before and after PTC124 treatment. In CHM3 RPE, mRNA levels were signif-
icantly lower than wild-type (equivalent to ~20%; p < 0.05; Fig. 5A), consistent with the observations on CHM3 
fibroblasts (Fig. 1C). The mRNA levels of DMSO-treated cells remained significantly different from wild-type 
(p < 0.05). PTC124 treatment did not significantly increase expression levels as compared to DMSO-treated cells 
(Fig. 5A). We then tested for an effect of PTC124 treatment on function. One representative prenylation assay is 
Figure 2. Effect of PTC124 treatment on CHM3 fibroblasts. (A) qPCR analysis of CHM mRNA levels in 
PTC124-treated patient fibroblasts. CHM transcript levels of CHM3 fibroblasts treated with DMSO (grey 
bar) remained significantly lower than wild-type levels (black bar). Data are expressed as mean ± SEM, n = 3; 
Mann and Whitney test *p < 0.05. Regardless of the dose of PTC124 used, CHM transcript levels (dotted 
bars) are not altered, as compared to DMSO-treated cells; Kruskal-Wallis test p > 0.05. NT = non-treated. 
(B) A representative in vitro prenylation assay showing biotinylated Rab proteins in wild-type (WT), and in 
non-treated (NT), DMSO-treated or PTC124-treated CHM3 fibroblasts. β-actin serves as a loading control. 
Bands were cropped from the same gel. (C) Quantification of the biotinylated Rab pool (in relative units), 
after normalisation to β-actin loading, in multiple independent assays shows a significant 10-fold increase 
in biotinylated Rabs in the non-treated (NT) and DMSO-treated fibroblasts of patient CHM3 (grey bars), as 
compared to wild-type (WT; black bar). Data are expressed as mean ± SEM; n is indicated in the corresponding 
histogram bars; Mann and Whitney test *p < 0.05. Treatment with a range of PTC124 doses did not significantly 
alter biotinylated Rab levels in CHM3 fibroblasts (dotted bars) as compared to DMSO-treated controls (red 
dotted line); Kruskal-Wallis test p > 0.05.
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shown in Fig. 5B, where it can be seen that wild-type iPSC-derived RPE had lower levels of biotinylated Rabs in 
comparison to untreated CHM3 RPE. Quantification of multiple assays showed that CHM3 iPSC-derived RPE 
had biotinylated Rab levels that were significantly higher than wild-type (p < 0.05; Fig. 5C). The biotinylated Rab 
levels of DMSO-treated CHM3 RPE remained significantly higher than wild-type (p < 0.05). Generally, all doses 
of PTC124, with the exception of the highest dose, showed a tendency to reduce biotinylated Rab levels, but this 
reduction was not statistically significant from DMSO-treated cells. The most pronounced reduction was a 30% 
decrease in Rab levels following treatment with 5 µg/ml PTC124.
To conclude, patient iPSC-derived RPE treated with PTC124 showed a non-significant decrease in cytosolic 
Rab levels at a larger range of doses than patient fibroblasts. However, the same 30% decrease was obtained in 
both cell types but at different doses.
In silico prediction and 3D modelling of Lys258 substitutions. The limited functional improvement 
in patient fibroblasts and iPSc-derived RPE suggested that PTC124 treatment, if mediating read-through, could 
not normalise the cell phenotype. It was shown that during translational read-through, not all amino acids are 
introduced at the target site with the same frequency31. In the case of PTC124-induced read-through of a UAA 
nonsense mutation in human cells, a tyrosine or a glutamine are introduced most frequently32. We therefore per-
formed an in silico analysis to determine the effect of these substitutions on human REP1. Six different software 
predicted that the p.Lys258Tyr substitution is damaging to REP1 function (Fig. 6A). Moreover, we used a 3D 
model of REP1 and Rab7 interaction, and showed that Lys258 could interact directly with the Glu188 residue in 
the C-terminal part of Rab7 (Fig. 6B). This, and the observation that Lys258 of REP1 is highly conserved among 
evolutionarily diverse species (Supplementary Fig. S3), suggest a critical role. Consistently, on the 3D model, 
Tyr258 was predicted to induce a local rearrangement of the structure due to steric clashes (Fig. 6C) and to dis-
rupt REP1-Rab7 interaction. In silico analysis predicted that the less frequent p.Lys258Gln substitution is also 
damaging to REP1 function, but with lower scores than the p.Lys258Tyr substitution (Fig. 6A). Analysis of the 
3D model predicted that Gln258 was better tolerated, but we could not definitively ascertain if this substitution 
affected REP1-Rab7 interaction (Fig. 6D).
Figure 3. Effect of cycloheximide (CHX) treatment on fibroblasts. (A) qPCR analysis of CHM mRNA levels 
in CHX-treated CHM3 fibroblasts (grey bars). CHX treatment increases CHM transcript levels in a time-
dependent manner, as compared to non-treated (NT) cells, with 24 h treatment resulting in significantly higher 
levels that exceed those of wild-type (WT; black bar). Data are expressed as mean ± SEM, n = 3; Kruskal-Wallis 
test *p < 0.05. (B) An in vitro prenylation assay using a biotinylated prenyl donor followed by western blot 
analysis shows a weak signal of incorporated biotin for the wild-type (WT) fibroblasts, as compared to the 
intense signal for the non-treated (NT), DMSO-treated or PTC124-treated CHM3 fibroblasts in the absence 
of CHX. By contrast, biotinylated Rab proteins cannot be detected in fibroblasts treated with CHX, coupled to 
or independent of PTC124 treatment. Bands were cropped from the same gel. (C) In vitro prenylation assay 
showing a time-dependent effect of CHX treatment on the biotinylated Rab population in both wild-type (WT) 
and CHM3 fibroblasts. Bands were cropped from the same gel. (D) Western blot analysis of CHX treatment 
on Rab27a expression in wild-type (WT) and CHM3 fibroblasts showing reduced expression levels from 8 h 
of CHX treatment in WT cells and from 2 h in CHM3 cells. REP1 expression in WT cells, as compared to 
CHM3 cells, is detected by hybridisation with an anti-REP1 antibody. In panels B–D, β-actin serves as a loading 
control. In panel D, bands were cropped from the same gel with a different exposure time for β-actin.
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Therefore, if PTC124 read-through of p.Lys258* is taking place, the incorporation of a glutamine at this criti-
cal position may account for the limited improvement in the prenylation defect.
Effect of proteasome inhibition concurrent to PTC124 treatment. As we observed a non-significant 
trend to functional improvement in iPSC-derived RPE, we tested for REP1 expression in PTC124-treated cells by 
western blot analysis. In parallel, we tried to enhance detection levels by treating the RPE with a commonly used pro-
teasome inhibitor, MG132, to prevent degradation of a mutant REP1 potentially produced post-read-through. The 
working MG132 concentration was determined by assaying for an increase in wild-type REP1 expression by western 
blot analysis. Following 24 h-treatment, all MG132 concentrations tested increased REP1 levels compared to untreated 
cells (Figs. 7A), and 2 µM resulted in the highest levels (Fig. 7B); proteasome inhibition was confirmed by assaying for 
an increase in poly-ubiquitinylated conjugates (data not shown). REP1 expression was then assayed by western blot 
analysis of CHM3 iPSC-derived RPE treated with PTC124 both in the absence (Fig. 7C) and presence (Fig. 7D) of 
MG132. Firstly, REP1 expression was not detected in non- or DMSO-treated CHM3 cells as compared to wild-type 
cells. Secondly, PTC124 treatment did not result in the detection of REP1 in CHM3 RPE (Fig. 7C). Lastly, MG132 used 
in conjunction with PTC124 did not improve the detection levels of REP1 in treated CHM3 cells (Fig. 7D).
Taken together, although a non-significant functional improvement was detected with PTC124 in 
iPSC-derived RPE, we could not detect the expression of REP1 even following inhibition of the proteasome.
Effect of PTC124 treatment using a UAA-mutated CHM overexpression system. Due to the unde-
tectable expression of REP1 in PTC124-treated patient fibroblasts and iPSC-derived RPE, we generated an over-
expression system to obtain higher REP1 levels. To this end, the CHM ORF, without the native 3′ stop codon, was 
cloned upstream of the ATG initiation codon of EGFP in the expression plasmid pEGFP-N3 to generate the fusion 
plasmid pCHM:EGFP. As compared to non-transfected cells (Fig. 8A), EGFP expression can be seen in CHM3 
fibroblasts transfected with pCHM:EGFP by immunofluorescence studies (Fig. 8B). Western blot analysis showed 
that REP1 was not detected in non-transfected  CHM3 fibroblasts whereas REP1:EGFP was detected in trans-
fected cells (Fig. 8C); REP1:EGFP was larger than native REP1 detected in wild-type fibroblasts. By site-directed 
mutagenesis, we then introduced the c.772A>T mutation into pCHM:EGFP, generating the UAA nonsense plasmid 
pCHM*:EGFP. Western blot analysis of transfected COS-7 cells detected REP1:EGFP in pCHM:EGFP-transfected 
cells but not in pCHM*:GFP-transfected cells (Fig. 8D). Furthermore, a fainter band corresponding to EGFP alone 
could be detected in all transfected cells, as compared to cells carrying the empty pEGFP-N3.
Figure 4. Generation of CHM3 iPSC and iPSC-derived RPE. qPCR analysis shows the mRNA levels of the 
host pluripotency markers OCT3/4 (A), LIN28 (B), SOX2 (C) and NANOG (D) in CHM3 iPSC (black bars) 
as compared to the original fibroblasts. Data are expressed as mean ± SEM, n = 3. (E) Karyotype analysis 
of the CHM3 iPSC did not detect large chromosomal rearrangements. (F) The pigmented, cobblestoned 
appearance of the iPSC-derived RPE monolayer. (G) qPCR analysis of the expression of the typical RPE markers 
MERTK, RDH5, TYR, ZO-1, PAX6, BEST1 and RLBP1 shows an upregulation of expression (in relative units) 
in the CHM3 iPSC-derived RPE (grey bars) as compared to fibroblasts (black bars). Data are expressed as 
mean ± SEM, n = 3. (H) Weekly recordings of the transepithelial resistance (TER) following P3 seeding are 
presented as normalized Ω/cm2. Data are expressed as mean ± SEM, n = 3.
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Transfected COS-7 cells were then treated with various PTC124 doses and assayed for mean EGFP fluo-
rescence intensity by flow cytometry (Fig. 8E). Firstly, pCHM:EGFP-transfected cells showed high EGFP levels 
compared to mock-transfected cells. Secondly, EGFP levels were moderately high in non- or DMSO-treated cells 
transfected with pCHM*:EGFP; consistent with the expression of EGFP alone detected by western blot analysis 
(Fig. 8D). Nonetheless, these EGFP levels were significantly lower than those of pCHM:EGFP-transfected cells 
(p < 0.05). Thirdly, PTC124 treatment of pCHM*:GFP-transfected cells did not significantly increase EGFP levels 
as compared to DMSO-treated controls, regardless of the dose. Lastly, western blot analysis of transfected COS-7 
cells treated with three representative PTC124 doses did not result in detectable REP1:EGFP production (Fig. 8E). 
This confirmed that the background EGFP levels were not masking the detection of a potential REP1:EGFP 
fusion protein produced post-read-through.
In conclusion, detection of a REP1 protein following PTC124 treatment of the CHM3 nonsense mutation was 
not improved using an artificial overexpression assay.
Discussion
IRDs lend themselves to different therapeutic possibilities, such as TRID therapy in the case of nonsense muta-
tions33. In this study, we assayed the potential for one particular TRID, PTC124, to correct the functional defect of 
the IRD CHM. CHM is an interesting target because a high percentage of causative CHM mutations are nonsense 
Figure 5. Effect of PTC124 treatment on CHM3 iPSC-derived RPE. (A) qPCR analysis of CHM mRNA levels 
in PTC124-treated patient iPSC-derived RPE (dotted bars). CHM transcript levels in non-treated (NT) and 
DMSO-treated CHM3 RPE (grey bars) are significantly lower than those of wild-type (WT; black bars) cells. 
Data are expressed as mean ± SEM, n = 3; Mann and Whitney test *p < 0.05. PTC124 treatment of CHM3 
iPSC-derived RPE, regardless of the concentration used, did not significantly alter CHM transcript levels as 
compared to DMSO-treated cells; Kruskal-Wallis test p > 0.05. (B) A representative in vitro prenylation assay 
showing biotinylated Rab proteins in wild-type (WT), and in non-treated (NT), DMSO-treated or PTC124-
treated CHM3 iPSC-derived RPE. β-actin serves as a loading control. Bands were cropped from the same gel. 
(C) Quantification of the relative biotinylated Rab levels in multiple independent assays, after normalisation 
to β-actin loading, shows a significant 4-fold increase in the non-treated (NT) or DMSO-treated iPSC-derived 
RPE of patient CHM3 (grey bars), as compared to wild-type RPE (WT; black bar). Data are expressed as 
mean ± SEM; n is indicated in the corresponding histogram bars; Mann and Whitney test *p < 0.05. Treatment 
with PTC124 results in a non-significant decrease in biotinylated Rab levels at all doses (dotted bars), with the 
exception of 100 µg/ml, as compared to DMSO-treated cells (red line); Kruskal-Wallis test p > 0.05.
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mutations20. PTC124 was recently shown to have a positive effect on the phenotype of the CHM zebrafish model, 
carrying a UAA nonsense mutation that gives rise to a p.Gln33* alteration25. We thus performed a complemen-
tary study on patient cells carrying a UAA mutation. This mutation is situated in exon 6 of CHM and gives rise to 
the p.Lys258* alteration.
PTC124 treatment of patient fibroblasts did not significantly alter CHM mRNA levels or biotinylated Rab 
levels. A tendency for a dose-dependent response was however noted; the best response was seen with 0.1 µg/ml 
PTC124, which mediated a 30% reduction. Interestingly, a significant 40% reduction in biotinylated Rab levels 
Figure 6. In silico analysis and 3D modelling of human REP1 and Rab7 interaction. (A) Predictions of various 
software on the impact of the amino acid substitutions p.Lys258Tyr (K258Y) and p.Lys258Gln (K258Q) on 
REP1 function. K258Y was predicted to be damaging by the software with relatively high accuracies and scores. 
K258Q was also predicted to be damaging at relatively lower accuracies and scores. ND = not determined. 
(B) The K258 residue (in grey) of REP1 may interact with the p.Glu188 (E188) residue of Rab7 via hydrogen 
bonds (yellow dots). (C) The introduction of a tyrosine at position 258 (Y258; in grey) is likely to induce a local 
rearrangement of REP1 due to steric hindrance (red areas around Y258) and would modify REP1-Rab7 binding. 
(D) The introduction of a glutamine at position 258 (Q258; in grey) is better tolerated, although an effect on 
REP1-Rab7 interaction could not be definitely ascertained.
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was observed in a previous study on CHM fibroblasts carrying the UAG nonsense mutation p.Tyr42* following 
treatment with ~10 µg/ml PTC12427. Here, concentrations >1 µg/ml tended to increase Rab levels. It was previ-
ously proposed that the type of nonsense mutation (UGA>UAG>UAA) and immediately downstream nucle-
otide (C>U>A≥G) could significantly impact TRID efficiency34. The p.Lys258* mutation is a UAA nonsense 
mutation followed by an A nucleotide. This could explain why the p.Tyr42* cells responded better to PTC124 than 
the p.Lys258* cells, as they carry a UAG nonsense mutation followed immediately by a U nucleotide. However, 
the CHM zebrafish model also carries a UAA mutation followed by an A nucleotide, like p.Lys258*, and it showed 
an even better response to PTC124 treatment than p.Tyr42* cells, with a normalisation of the prenylation defect. 
Therefore, our data suggest that the type of premature stop codon or surrounding sequence might not be the only 
factors accounting for the differences in PTC124 efficacy, at least in the case of CHM.
We tried to improve PTC124 efficiency by blocking NMD. Regardless of the concentration or incubation 
time, CHX treatment caused a disappearance of the Rab pool independently of PTC124 in both wild-type and 
patient fibroblasts. The effect was thus independent of a nonsense mutation and NMD inhibition. In addition, a 
CHX-induced decrease in Rab27a expression was also observed, suggesting that CHX treatment had an effect on 
protein synthesis, as previously reported35. This decrease was more pronounced in patient cells as compared to 
wild-type, maybe because, in the latter, the majority of Rab27a is prenylated and membrane-associated, and hence 
more stable. By contrast, in patient cells, a large proportion of Rab27a is unprenylated and thus more susceptible 
to degradation. This is consistent with the observation that CHX treatment did not affect the expression of REP1, 
which is present as part of the prenylation complex in wild-type cells, or β-actin, which is part of the cytoskeleton 
complex in wild-type and patient cells. In a similar manner, the dual activity of CHX negatively impacted the 
functional studies of long QT syndrome 2 due to nonsense mutations in the gene hERG36.
As the retina is the main tissue type to show clinical signs in patients, it has been hypothesised that REP1 activ-
ity is more critical in this tissue37. Therefore, PTC-induced functional improvement may be dependent on the cell 
type, as was shown for other diseases38. We thus generated a pertinent human cell model by reprogramming the 
UAA-carrying fibroblasts into iPSC, which were differentiated into RPE, one of the primary tissues affected in 
CHM. PTC124 treatment of the iPSC-derived RPE resulted in a non-significant decrease of biotinylated Rabs at a 
large range of doses; the best response was seen with 5 µg/ml, which decreased Rabs by 30%. Therefore, if PTC124 
treatment was performing read-through of the UAA nonsense mutation in fibroblasts and iPSC-derived RPE, it 
could not normalise the cellular phenotype.
This may not be surprising, as it has been shown that not all amino acids are introduced into the target site 
at the same frequency during translational read-through31. Therefore, the wild-type residue will only be inserted 
a percentage of the time, if at all. In the case of PTC124-induced translational read-through of a UAA nonsense 
mutation, a tyrosine (~60% of cases) or a glutamine (~40%) is introduced32. However, both substitutions were 
predicted to be relatively damaging to human REP1 function by in silico analysis. Moreover, 3D modelling pre-
dicted that Lys258 of REP1 interacts with Rab7. This critical role is consistent with its high conservation among 
evolutionarily diverse species. Consistently, Tyr258 was predicted to disrupt REP1-Rab7 interaction but the effect 
of Gln258 could not be ascertained. Taken together, in the majority of cases, PTC124 read-through of p.Lys258* 
would produce a deleterious mutant protein.
Figure 7. Effect of MG132 treatment on wild-type and CHM3 iPSC-derived RPE. (A) Western blot analysis of 
REP1 expression following treatment of wild-type iPSC-derived RPE with increasing concentrations of MG132. 
β-actin serves as a loading control. Bands were cropped from the same gel with different exposure times for 
REP1 and β-actin. (B) Quantification of REP1 expression in panel A shows an increase at all concentrations 
used with the highest levels observed at 2 µM (~5-fold higher than non-treated (NT) cells). Western blot 
analysis of REP1 expression in non-treated (NT), DMSO-treated or PTC124-treated CHM3 iPSC-derived RPE 
in the absence (C) or presence (D) of MG132. β-actin serves as a loading control. No expression could be seen 
in CHM3 iPSC-derived RPE as compared to wild-type (WT) RPE regardless of the treatment used. In panels C 
and D, bands were cropped from the same gel with different exposure times for REP1 and β-actin.
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Figure 8. Effect of PTC124 treatment on a UAA-mutated CHM overexpression system. Immunofluorescence 
studies with an anti-GFP antibody of mock-transfected (A) and pCHM:EGFP-transfected (B) CHM3 fibroblasts 
showing EGFP expression (in green; nuclei in blue). (C) Western blot analysis of transfected CHM3 fibroblasts 
using an anti-REP1 antibody. An ~90 kDa REP1 band is detected in wild-type (WT) cells but not in mock-
transfected cells. A larger (~120 kDa) REP1:EGFP band is seen in pCHM:EGFP-transfected cells. β-actin serves 
as a loading control. The WT and CHM3 lanes were cropped from two different gels. (D) Western blot analysis 
of transfected COS-7 cells using an anti-EGFP antibody. No signal can be detected in mock-transfected cells. 
An ~25 kDa EGFP band can be detected in cells transfected with the empty pEGFP-N3 plasmid. An ~120 kDa 
REP1:EGFP band is seen in pCHM:EGFP-transfected cells but not in pCHM*:EGFP-transfected cells; a faint 
~25 kDa EGFP band is detected in both. Bands were cropped from the same gel with different exposure times 
for EGFP and β-actin. (E) Flow cytometry analysis of the mean fluorescence intensity of transfected COS-7 cells 
treated with various doses of PTC124. A 25- and 14-fold increase in fluorescence is seen in cells transfected with 
pCHM:EGFP (black bar) and pCHM*:EGFP (grey bars), respectively, as compared to mock-transfected cells. 
There was a significant 1.8-fold difference in intensity in non- and DMSO-treated pCHM*:EGFP-transfected cells 
as compared to pCHM:EGFP-transfected cells. Data are expressed as mean ± SEM, n = 2; Mann and Whitney test 
*p < 0.05. These levels did not significantly increase following PTC124 treatment (dotted bars) as compared to 
DMSO-treated controls (red dotted line); Kruskal-Wallis test p > 0.05. NT = non-treated. (F) Western blot analysis 
of transfected COS-7 cells following treatment with PTC124 using an anti-EGFP antibody. No signal is detected 
in mock-transfected cells. An ~120 kDa REP1:EGFP band is seen in pCHM:EGFP-transfected cells but not in 
non-treated (NT), DMSO-treated or PTC-124-treated pCHM*:EGFP-transfected cells. An ~25 kDa EGFP band 
is detected in all transfected cells, which is more intense for the pCHM*GFP-transfected cells. β-actin serves as a 
loading control. Bands were cropped from the same gel with different exposure times for β-actin.
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It is tempting to speculate that Gln258 may allow residual REP1 function that could account for the decrease 
in Rab levels, but that was not sufficient to reach significance. Along this line, in the case of a UAG nonsense 
mutation, a glutamine (~53%), tyrosine (~44%) or tryptophan (~1%) residue are incorporated most frequently32. 
Therefore, for the p.Tyr42* mutation, the wild-type amino acid has a relatively high chance of being incorpo-
rated following read-through, which could account for the significant prenylation rescue observed post-PTC124 
treatment27. Similarly, in the case of the p.Gln33* UAA nonsense mutation carried by the CHM zebrafish model, 
the wild-type glutamine would be incorporated relatively frequently. Moreover, the Gln33 residue is not evo-
lutionarily conserved suggesting that non-wild-type substitutions, such as a tyrosine, could also be relatively 
well-tolerated26. This cumulative effect could explain the normalisation of the biochemical phenotype following 
PT124 treatment of the chm−/y zebrafish larvae27.
In general, REP1 tolerance to amino acid changes is still in debate. If we take into account genotype data-
sets of large populations such as ExAC39, the expected (116) and observed (112) number of CHM missense 
variants is highly similar (see http://exac.broadinstitute.org/gene/ENSG00000188419). The majority of these 
variants are considered to be clinically neutral. Interestingly, the first pathogenic missense CHM variant was 
reported in 200940 whereas gene screening began 20 years prior41. To date, nine CHM-associated variants have 
been reported (see http://www.lovd.nl/CHM), and only three have been proven to be pathogenic29,40,42. This low 
number remains unexplained. Particularly pertinent for this study, is that the missense-encoded mutant REP1 is 
not always detected by western blot analyses suggesting this protein is highly sensitive to certain modifications40. 
This could be paralleled to the lack of a detectable REP1 following PTC124 treatment of p.Lys258*-carrying and 
p.Tyr42*-carrying cells. We show here that the detection limit of western blot analysis for REP1 is between 2 
and 10% of wild-type levels. Therefore, this implies that, despite the significant functional rescue in the p.Tyr42* 
study, REP1 levels were below 10%. It is questionable that such low levels could give rise to a clinical benefit if 
we consider that, in the zebrafish model, the residual maternal rep1 derived from the persistent yolk sac in 6 dpf 
larvae is estimated at ~15% and this is not sufficient to mediate normal development and prevent lethality27.
To increase the REP1 detection threshold following PTC124 treatment of p.Lys258* iPSC-derived RPE, we 
inhibited the proteasome prior to western blot analysis, but still did not detect the protein. We therefore designed 
an artificial overexpression system containing the same mutation carried by the patient cells to increase REP1 
levels. By fusing EGFP to the mutant CHM gene, we used flow cytometry and western blot analysis to assay for 
REP1:EGFP production post-treatment. The fusion construct showed high background fluorescence levels, which 
were due to the expression of EGFP alone, however PTC124-treatment did not significantly increase fluores-
cence beyond background. Furthermore, a REP1:EGFP protein could not be detected by western blot analysis. 
Therefore, in the absence of detectable REP1, it is difficult to conclude that the effect observed post-PTC124 
treatment of p.Lys258* is due to read-through of the nonsense mutation.
To date, the efficiency of PTC124 has been highly controversial43. In the case of Duchenne muscular dys-
trophy15, cystic fibrosis44, Usher syndrome 1C45, retinitis pigmentosa17,18 and anirida19, PTC124 was suggested 
to improve cellular phenotype. By contrast, in the case of long-QT syndrome type 146, lysosomal storage disor-
ders47, conduction disease and potential lethal arrhythmias48, infantile neuronal ceroid lipofuscinosis38 and leptin 
receptor-associated obesity49, PTC124 was ineffective. It may be that the answer to these discrepancies could 
lie in the characteristics of the target amino acid. This may also explain why only a subgroup of patients in the 
Duchenne muscular dystrophy phase 3 clinical responded to PTC124 treatment50.
In conclusion, in the case of the p.Lys258* mutation, we do not have firm evidence that PTC124 did accom-
plish read-through. However, if read-through were taking place, we highlight other considerations such as con-
servation or type of the target amino acid that may prevent the production of a functional protein. This may 
suggest that different nonsense mutations for the same gene might be less prone to read-through, in agreement 
with other studies51. Therefore, to render TRID therapy more effective, a personalised, rather than a widespread, 
approach may need to be considered, whereby patient cells are screened in vitro for drug efficiency prior to inclu-
sion in a clinical trial.
Methods
Skin biopsy and fibroblast culture. The skin biopsy of a 10 year-old boy (CHM3) carrying a UAA non-
sense mutation was performed at the Centre of Reference for Genetic Sensory Disorders (CHRU Montpellier, 
France) according to local guidelines and regulations. Informed consent was obtained from the subject’s mother. 
All experimental protocols were approved by the National Agency for Health and Medicine under the biomedical 
research authorisation number 2014-A00549-38. The corresponding fibroblasts were cultured in AmnioMAX 
C100 basal media with GlutaMAX (Gibco, ThermoFisher Scientific, Villebon sur Yvette, France) containing 10% 
decomplemented foetal calf serum (FCS; Lonza, Verviers, Belgium), 1% penicillin-streptomycin-amphotericin B 
(Lonza) and 2% AmnioMax-C100 supplement (Gibco) at 37 °C under 5% CO230.
Generation of iPSC. The CHM3 fibroblasts were seeded on day (D) −1 at a density of 2 × 105 cells per 
9.4 cm2 in high glucose DMEM containing GlutaMAX and sodium pyruvate (Gibco) and supplemented with 
10% FCS, 1% non-essential amino acids (Gibco), 1 mM L-ascorbic acid (Sigma-Aldrich, Saint Quentin Fallavier, 
France) and 10 ng/ml bFGF (Peprotech, Neuilly Sur Seine, France). On D0, cells were reprogrammed using the 
CytoTune-iPS 1.0 Reprogramming kit (Life Technologies, ThermoFisher Scientific) containing four Sendai 
virus-based reprogramming vectors expressing OCT4, SOX2, KLF4 and c-MYC at an MOI of 3. On D1, the media 
was refreshed, and, on D5, the transduced fibroblasts were passaged onto feeder cells (prepared as described28) 
at a density of 105 cells per 9.4 cm2. On day 6, the media was changed to ES media: Knockout DMEM (Gibco) 
supplemented with 20% KO serum replacement (Gibco), 200 mM GlutaMAX (Gibco), 1% non-essential amino 
acids, 0.1% β-mercaptoethanol (Gibco), 1% penicillin-streptomycin (Gibco) and 10 ng/ml bFGF, and (until D11) 
500 µM Valproic acid (Sigma-Aldrich). Resulting iPSC were mechanically passaged and subsequently adapted to 
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feeder-free conditions on a 1/100 dilution Corning Matrigel HESC-qualified matrix (Analytic Lab, St Mathieu 
de Treviers, France) and in Essential (E) 8 media (Gibco). Passages were subsequently performed using Versene 
solution (Gibco).
Karyotype analysis. iPSC were grown to 50% confluence, treated with 0.1% Nocodazole (Sigma-Aldrich) 
and the pellet prepared as previously described29. Karyotype analyses were performed by the Chromostem facility 
(CHRU Montpellier, France).
Generation of iPSC-derived RPE. The iPSC were grown to confluence and the E8 media was changed 
to bFGF-depleted ES media to initiate spontaneous differentiation. Pigmented foci were manually dissected, 
dissociated and seeded as previously described29. For TER measurements, iPSC-derived RPE was seeded on 
Matrigel-coated BD Falcon cell culture inserts (Dominique Dutscher, Brumath, France). TER was measured 
using the Epithelial Volt/Ohm Meter EVOM2 (World Precision Instruments, Hertfordshire, U.K.) as described29.
Mutation verification. To verify the presence of the c.772A>T variant situated in exon 6 in cultured cells, 
genomic DNA was isolated using the DNeasy Blood & Tissue Kit (Qiagen, Les Ulis, France) according to the 
manufacturer’s instructions. A 768-bp product was then amplified using the F primer 5′-GGG TAG GGA GGT 
TCA CTG GA-3′ and the R primer 5′- AAA TCA CCA CGG AGG ACT GG-3′. This amplicon was cleaned using 
the ExoSAP-IT PCR Clean-up Kit (GE Healthcare, Velizy Villacoublay, France) prior to sequencing with the F 
primer 5′-ATC TTT ATT GTT TTC CAA TT-3′ and the BigDye Terminator Cycle Sequencing Ready Reaction 
kit V3.1 on a 3130xL Genetic Analyser (Applied Biosystems, Foster City, CA).
Reverse transcription and quantitative PCR studies. RNA was isolated and 150 ng was reverse tran-
scribed as described29. Quantitative RT-PCR (qPCR) was used to analyse the expression of endogenous CHM in 
fibroblasts and iPSC-derived RPE, and the endogenous pluripotency genes OCT3/4, LIN28, SOX2 and NANOG 
in iPSC, using the previously described primers28. qPCR was used to analyse the expression of the RPE genes 
MERTK, RDH5, TYR, ZO1, PAX6, BEST1 and RLBP1 in iPSC-derived RPE, and primer sequences are avail-
able upon request. All results were normalised to GAPDH expression. Reactions were performed using the 
LightCycler® 480 SYBR Green I Master mix on a LightCycler® 480 II thermal cycler (Roche). Results were ana-
lysed using LightCycler® 480 software and the Microsoft Excel programme.
Generation of pCHM:EGFP fusion constructs. The wild-type CHM ORF was amplified using the SacI 
site-containing F primer 5’- GAG CTC ATG GCG GAT ACT CTC CCT TC-3’ and the R primer 5′-GGT ACC 
TTC AGA GGA CTC CTC TAG GT-3′, containing a KpnI site at the place of the CHM stop codon, and subcloned 
using the pGEM-T Easy vector system (Promega, Charbonnières-les-Bains, France). Following digestion with the 
restriction enzymes SacI and KpnI, the CHM ORF was then subcloned into the Clontech pEGFP-N3 expression 
plasmid (Ozyme, Saint-Quentin-en-Yvelines, France) to generate the pCHM:EGFP fusion construct. The c.772A>T 
variant was then introduced into the wild-type plasmid to generate the plasmid pCHM*:EGFP using the Stratagene 
QuikChange site-directed mutagenesis kit (Agilent, Les Ulis, France) and the F primer 5′-GTT AGT CGA TAT 
GCA GAG TTT TAA AAT ATT ACC AGG ATT CTT G-3′, with its reverse complementary primer.
Immunofluorescence studies. One million CHM3 fibroblasts were nucleofected with 1 µg DNA of the 
pCHM:EGFP fusion plasmid and 100 µl of P2 Primary Cell 4D-Nucleofector solution (Lonza, Levallois-Perret, 
France) using the program EN-150 of the Amaxa 4D-Nucleofector according to the manufacturer’s instructions. 
Non-transfected and transfected cells were then seeded in four 1.9 cm2 wells containing glass coverslips. Media 
was refreshed the following day and, 72 h post-nucleofection, cells were fixed with 4% Alfa Aesar paraformalde-
hyde (PFA; ThermoFisher Scientific), blocked in 5% FCS and 1% bovine serum albumin (BSA; Sigma-Aldrich), 
and permeabilised with 0.2% Triton X-100 (Sigma-Aldrich). The coverslips were then incubated with a 1:200 
dilution of rabbit anti-GFP antibody (Invitrogen-Molecular probes) overnight at 4 °C and with a 1:1000 dilu-
tion donkey anti-rabbit IgG-Alexa Fluor 488 secondary antibody containing 0.2 µg/ml bisBenzimide Hoechst 
(Sigma-Aldrich) for 45 min at room temperature prior to mounting in Dako Fluorescent Mounting Media (Dako 
France SAS, Les Ulis, France).
Drug treatments. PTC124 was purchased from Selleck Chem (Euromedex, Souffelweyersheim, France) and 
dissolved in DMSO (ThermoFisher Scientific) to a stock concentration of 50 mg/ml. Cells were treated in media 
without antibiotics at various working concentrations (ranging from 0.01 µg/ml to 100 µg/ml) but always at the 
same final concentration of DMSO (0.2%) as the mock-treated controls (treated with DMSO alone). Cells were 
treated for 24 h and dosed twice in that period. In the case of fibroblasts, cells were generally seeded at 2 × 105 
cells per 9.4 cm2 and treated 24 h post-seeding. iPSC-derived RPE was used at passage 3 upon maturity (from 
~8 weeks post-differentiation). To increase CHM mRNA levels, fibroblasts were treated with 20, 100 or 500 µg/
ml cyclohexamide (Sigma-Aldrich) for 2 to 24 h in the absence or presence of PTC124. To increase REP1 levels, 
iPSC-derived RPE was treated with 2 to 10 µM MG132 (Tocris Bioscience, Lille, France) in the absence or pres-
ence of PTC124 for 24 h.
Transfection and flow cytometry. COS-7 cells were seeded at a density of 7.5 × 104 cells per 1.9 cm2 in 
DMEM containing GlutaMAX (Gibco) supplemented with 10% FCS. Twenty-four h post-seeding cells were trans-
fected using 1 µg DNA of the pCHM:EGFP fusion plasmids and 1.25 µl Lipofectamine 3000 transfection reagent 
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(Thermo Fisher Scientific, Courtaboeuf, France) according to the manufacturer’s instructions. Twenty-four h 
post-transfection, the media was changed to fresh media containing PTC124, and 48 h post-transfection the cells 
were collected and analysed using a BD Accuri C6 Flow Cytometer (BD Biosciences, Le Pont de Claix, France).
Western blot analyses and in vitro prenylation assays. For the western blot analyses, cells were 
scraped into cold PBS containing protease inhibitors, resuspended in Laemmli’s sample buffer and analysed as 
previously described29. Similarly for the in vitro prenylation assays, pelleted cells were resuspended in degased 
prenylation lysis buffer and the unprenylated cytosolic Rab pool was analysed as described29. Quantifications were 
performed using the Image J software and expressed as a function of the β-actin signal.
Statistical analyses. For the comparison of two groups of data, a Mann and Whitney test was used. For 
the comparison of three or more groups, a Kruskal-Wallis ANOVA was performed followed by a post-hoc 2 × 2 
comparison52.
In silico predictions and 3D modelling. The predictive effect of putative amino acid change on 
REP1 function was analysed using the online prediction programs PolyPhen-2 HumVar, SIFT, SNAP, PMut, 
MutationAssessor.org and PROVEAN software. The CHM and REP1 reference sequences used were RAE1_
HUMAN, NP_000381 and ENSP00000350386. The 3D structure used to perform the analysis was a homology 
model derived from the Protein Data Bank (http://www.rcsb.org/) structure 1vg0_A (raw data kindly provided 
by Dr. Sergeev, NIH, Bethesda, USA) that was previously reported53. Pictures were drawn using the PyMOL 
Molecular Graphics System, (Version 1.8 Schrödinger, LLC, New York, USA).
Data Availability Statement. All data generated or analysed during this study are included in this pub-
lished article (and its Supplementary Information file).
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